Launch week offerEnds in00h00m00s

annual Promonthly Pro

Emmanouil Sifakis

Karolinska Institutet

Sweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Sweden Professors in Cell Biology Cell Biology professors in Sweden

Articles (28)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (14)

Amjad Alkodsi

University of Helsinki

FINLAND

View details

Charles Perou

Professor

University of North Carolina

UNITED STATES

View details

Jonas Bergh

Karolinska University Hospital

SWEDEN

View details

Ioannis Zerdes

Karolinska University Hospital

SWEDEN

View details

Narsis Kiani

Karolinska Institutet

SWEDEN

View details

Nikos Tsiknakis

Karolinska Institutet

SWEDEN

View details

Balazs Acs

Associate Professor

Karolinska Institutet

SWEDEN

View details

Nikolas Herold

Karolinska University Hospital

SWEDEN

View details

Johan Hartman

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN

View details

Theodoros Foukakis

Karolinska Institutet

SWEDEN

View details

Roxanna Hellgren

Karolinska Institutet

SWEDEN

View details

Xinsong Chen

Karolinska University Hospital

SWEDEN

View details

Apple Tay

Karolinska Institutet

SWEDEN

View details

Rolf Ohlsson

senior professor

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emmanouil Sifakis

Research Interests

Make your next move.

Explore related searches

Articles (28)

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2-breast cancer: a randomized phase II trial

Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer

Glucocorticoid prophylaxis influences the systemic immune macroenvironment in patients with early stage, treatment naïve, HER2+ breast cancer

Assessment of Trophoblast cell surface antigen 2 (Trop-2) expression and its clinical significance in breast cancer: a multi-level analysis of protein and gene expression.

Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations.

Clonal evolutionary trajectory of HER2-positive breast cancer with ERBB2 or PIK3CA mutations under neoadjuvant treatment

Abstract PS2-08-01: A predictive gene signature for benefit from dose-dense adjuvant chemotherapy in patients with high-risk early breast cancer: results from the PANTHER phase III trial

Abstract PS3-11-24: The Combined Immune-Stromal Score (CISS): A Novel Prognostic Gene Signature in Early both ER-positive and HER2-positive Breast Cancer

Computational pathology annotation enhances the resolution and interpretation of breast cancer spatial transcriptomics data.

Abstract P4-01-30: Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment

BreastSubtypeR: Streamlining Intrinsic Molecular Subtyping in Breast Cancer Research with a User-Friendly R Package

Gene Expression patterns in early ER+/HER2-breast cancer treated with neoadjuvant chemotherapy versus CDK4/6 inhibitor therapy: results from the Swedish PREDIX Luminal B trial

20P Evolution of early-stage ERBB2-mutant, HER2+ breast cancer under neoadjuvant therapy

30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy

4MO Development and validation of CDKPredX, a novel predictor of response to neoadjuvant endocrine therapy and CDK4/6 inhibitors versus chemotherapy in ER+/HER2- breast cancer: Correlative analysis of the randomized phase II PREDIX luminal B trial

55P Single-nucleotide polymorphisms associated with haematological toxicities during adjuvant chemotherapy in high-risk early breast cancer patients: Results from the PANTHER phase III trial

77P The landscape of somatic mutations in high-risk early ER+/HER2- breast cancer patients: Analysis of the randomized phase II PREDIX luminal B trial

Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

Transcriptomic profiles of endocrine-resistant breast cancer

BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast cancer research

Combined immune-stromal score (CISS) is prognostic in early ER-positive/HER2-positive breast cancer

Clinical course and molecular characteristics of oligometastatic breast cancer: Results from two randomized neoadjuvant trials

Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment

Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction

Author Correction: WNT signaling and AHCTF1 promote oncogenic MYC expression through super-enhancer-mediated gene gating

MYC as a driver of stochastic chromatin networks: implications for the fitness of cancer cells

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease

PD-1 protein and gene expression as prognostic factors in early breast cancer

Collaborators (14)

Amjad Alkodsi

Charles Perou

Jonas Bergh

Ioannis Zerdes

Narsis Kiani

Nikos Tsiknakis

Balazs Acs

Nikolas Herold

Johan Hartman

Theodoros Foukakis

Roxanna Hellgren

Xinsong Chen

Apple Tay

Rolf Ohlsson

Make your next move.